TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company reported strong financial performance with a 35% YoY revenue increase and improved gross margins. Net income turned positive, and cash flow improved significantly. Despite risks related to regulatory hurdles and market conditions, the optimistic guidance and strategic initiatives, such as international expansion and new product development, suggest potential growth. With a market cap of $4.87 billion, the positive earnings and guidance are likely to result in a moderate stock price increase, falling in the positive range (2% to 8%).
Key Financial Performance
Revenue TransMedics reported revenue of $42.1 million for Q4 2025, representing a 35% increase year-over-year. This growth was driven by strong demand for the OCS technology and increased adoption across multiple transplant centers.
Gross Margin The gross margin for Q4 2025 was 72%, up from 68% in Q4 2024. The improvement was attributed to operational efficiencies and higher production volumes.
Operating Expenses Operating expenses for Q4 2025 were $25.3 million, a 20% increase compared to the same period last year. The rise was due to investments in sales and marketing as well as research and development initiatives.
Net Income Net income for Q4 2025 was $5.2 million, compared to a net loss of $1.8 million in Q4 2024. This turnaround was primarily due to increased revenue and improved gross margins.
Cash Flow The company generated $8.7 million in operating cash flow during Q4 2025, up from $3.5 million in Q4 2024. The increase was driven by higher profitability and efficient working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements are subject to risks and uncertainties, which could impact future events, results, or performance. This includes potential challenges in achieving expected growth, revenue, gross margins, and operating expenses.
Regulatory hurdles: The discussion implied that regulatory approvals and compliance could pose challenges to the company's operations and strategic objectives.
Market conditions: Potential risks related to market conditions were mentioned, which could affect the commercial opportunity of products and services.
Strategic execution risks: Challenges in executing new clinical programs and achieving their potential timing, benefits, or outcomes were highlighted as risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Financial Expectations: Expectations for growth in the organization, guidance, and/or expectations for revenue, gross margins, and operating expenses in 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blair LLC
CFO Treasurer
Canaccord Genuity
Conference reminder
Corp Research
Cowen Research
Day Canaccord
Director Gerardo
Division Jennings
Division Mardula
Division Markowitz
Division Matson
Division Pasquale
Division Rescott
Division Suraj
Division Zachary
EST afternoon
Gerardo Hernandez
Hassanein Founder
Hernandez CFO
Kalia Oppenheimer
LLC PM
LLC Research
Mardula Blair
Morgan Gilmartin
PM EST
Rescott Baird
Research Division
Research LLC
Suraj Kalia
Waleed Hassanein
benefit outcome
comment statement
timing benefit
TMDX Transcript
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates strong financial performance with a 35% YoY revenue increase, improved gross margins, and a 67% rise in net income. Despite the strategic investment risks, the company's aggressive growth initiatives in organ transplant therapy could drive future success. The market cap suggests a moderate reaction, leading to a positive outlook for stock price movement in the next two weeks.
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
Positive2-25
The company reported strong financial performance with a 35% YoY revenue increase and improved gross margins. Net income turned positive, and cash flow improved significantly. Despite risks related to regulatory hurdles and market conditions, the optimistic guidance and strategic initiatives, such as international expansion and new product development, suggest potential growth. With a market cap of $4.87 billion, the positive earnings and guidance are likely to result in a moderate stock price increase, falling in the positive range (2% to 8%).
TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call reveals strong financial performance with raised revenue guidance and optimistic growth projections. The Q&A section highlights management's confidence in achieving targets and the potential of next-gen programs. International expansion and strategic partnerships are likely to enhance growth. Despite some uncertainties, the overall sentiment is positive, with a focus on growth and expansion.
TMDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
